{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:11:27Z","timestamp":1788016287346,"version":"build-2784847793"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.semarthrit.2024.152417","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T06:59:42Z","timestamp":1707721182000},"page":"152417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Identification of new risk factors for hydroxychloroquine and chloroquine retinopathy in systemic lupus erythematosus patients"],"prefix":"10.1016","volume":"66","author":[{"given":"Ludovic","family":"Trefond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Lhote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Mathian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Pineton","family":"de Chambrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheline","family":"Pha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Hie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Miyara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Papo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Moyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dov","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Saade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thouraya Ben","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Haroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Chasset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur Cohen","family":"Aubart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00ebl","family":"Zahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2024.152417_bib0001","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2133.1958.tb13313.x","article-title":"Plaquenil in the treatment of cutaneous lupus erythematosus","volume":"70","author":"Goode","year":"1958","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0002","first-page":"323","article-title":"The efficacy of antimalarials in systemic lupus erythematosus","volume":"2","author":"Rudnicki","year":"1975","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0003","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1529-8019.2007.00131.x","article-title":"New concepts in antimalarial use and mode of action in dermatology","volume":"20","author":"Kalia","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0004","series-title":"Syst. lupus erythematous","first-page":"1061","article-title":"Antimalarials and systemic lupus erythematosus","author":"Costedoat-Chalumeau","year":"2010"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0005","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0006","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41584-018-0111-8","article-title":"Hydroxychloroquine retinopathy - implications of research advances for rheumatology care","volume":"14","author":"Jorge","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0007","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1093\/rheumatology\/keab844","article-title":"Risk of hydroxychloroquine retinopathy in the community","volume":"61","author":"Dabit","year":"2022","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0008","first-page":"1171","article-title":"Two years\u2019 experience of screening for hydroxychloroquine retinopathy","volume":"35","author":"Gobbett","year":"2021","journal-title":"Eye Lond Engl"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0009","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"American Academy of Ophthalmology, recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0010","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol D\u00e9c"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0011","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/art.41121","article-title":"Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy","volume":"72","author":"Petri","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0012","first-page":"keaa157","article-title":"Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case\u2013control study with hydroxychloroquine blood-level analysis","author":"Lenfant","year":"2020","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0013","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/acr.20133","article-title":"Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000789","article-title":"Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine","volume":"9","author":"Almeida-Brasil","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0015","doi-asserted-by":"crossref","DOI":"10.7326\/M22-2453","article-title":"Hydroxychloroquine dose and risk for incident retinopathy : a cohort study","author":"Melles","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0016","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12920-022-01171-6","article-title":"Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions","volume":"15","author":"Gao","year":"2022","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0017","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.toxrep.2014.10.019","article-title":"Chloroquine and hydroxychloroquine binding to melanin: some possible consequences for pathologies","volume":"1","author":"Schroeder","year":"2014","journal-title":"Toxicol Rep"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0018","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.11531","article-title":"Systemic lupus erythematosus may be a risk factor for antimalarial-induced retinopathy compared with other rheumatologic diseases","author":"Liu","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0019","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0020","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0021","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archderm.1988.01670060015008","article-title":"The validity and practicality of sun-reactive skin types I through VI","volume":"124","author":"Fitzpatrick","year":"1988","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0022","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0023","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0024","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/FTD.0000000000000614","article-title":"Development and validation of a fast ultra-high performance liquid chromatography-fluorescent method for the quantification of hydroxychloroquine and its metabolites in patients with lupus","volume":"41","author":"No\u00e9","year":"2019","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0025","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"American Academy of Ophthalmology, Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy","volume":"118","author":"Marmor","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0026","article-title":"Hydroxychloroquine is metabolized by CYP2D6, CYP3A4, and CYP2C8, and inhibits CYP2D6, while its metabolites also inhibit CYP3A in vitro","author":"Paludetto","year":"2022","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0027","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/BF02976712","article-title":"Cytochrome P450 2C8 and CYP3A4\/5 are involved in chloroquine metabolism in human liver microsomes","volume":"26","author":"Kim","year":"2003","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0028","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/art.39402","article-title":"Association of Polymorphisms of Cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus","volume":"68","author":"Lee","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0029","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1211\/0022357022340","article-title":"Absorption, distribution and excretion of 14C-chloroquine after single oral administration in albino and pigmented rats: binding characteristics of chloroquine-related radioactivity to melanin in-vivo","volume":"55","author":"Ono","year":"2003","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1389200023338017","article-title":"Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update","volume":"3","author":"Hemeryck","year":"2002","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0031","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152417_bib0032","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0773.1983.tb01080.x","article-title":"Citalopram-induced generalized lipidosis in rats","volume":"52","author":"L\u00fcllmann-Rauch","year":"1983","journal-title":"Acta Pharmacol Toxicol Copenh"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152417_bib0033","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40123-021-00340-7","article-title":"Presumed sertraline-associated maculopathy: a case series","volume":"10","author":"Javidi","year":"2021","journal-title":"Ophthalmol Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152417_bib0034","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/ard.48.5.358","article-title":"Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the \u201cprimary\u201d antiphospholipid syndrome","volume":"48","author":"Asherson","year":"1989","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0035","series-title":"Chloroquine and hydroxychloroquine toxicity","author":"Stokkermans","year":"2022"},{"issue":"1A","key":"10.1016\/j.semarthrit.2024.152417_bib0036","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","article-title":"Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate","volume":"75","author":"McChesney","year":"1983","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0037","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.colsurfb.2015.06.040","article-title":"Physical factors affecting chloroquine binding to melanin","volume":"134","author":"Schroeder","year":"2015","journal-title":"Colloids Surf B"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0038","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/0006-2952(81)90021-6","article-title":"Studies on the binding of chlorpromazine and chloroquine to melanin in vivo","volume":"30","author":"Tj\u00e4lve","year":"1981","journal-title":"Biochem Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2024.152417_bib0039","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1177\/0961203396005001131","article-title":"The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review","volume":"5","author":"Wallace","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0040","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0041","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/s41433-020-01380-2","article-title":"The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary","volume":"35","author":"Yusuf","year":"2021","journal-title":"Eye"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0042","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0043","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ophtha.2014.10.015","article-title":"Spectral-domain optical coherence tomography in hydroxychloroquine retinopathy","volume":"122","author":"Johnston","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0044","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/OPTH.S163451","article-title":"Somatotype, the risk of hydroxychloroquine retinopathy, and safe daily dosing guidelines","volume":"12","author":"Browning","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.semarthrit.2024.152417_bib0045","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/art.41497","article-title":"Early-onset hydroxychloroquine retinopathy and a possible relationship to blood levels: comment on the Article by Petri et al","volume":"73","author":"Yokogawa","year":"2021","journal-title":"Arthritis Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224000544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224000544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T01:46:48Z","timestamp":1718416008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224000544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":45,"alternative-id":["S0049017224000544"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152417","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of new risk factors for hydroxychloroquine and chloroquine retinopathy in systemic lupus erythematosus patients","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152417"}}